AMAG Pharma (AMAG) Reports Q3 Loss of $4.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to AMAG Pharma (AMAG) Reports Q3 Loss of $4.31/Share
November 6, 2017 8:07 AM EST
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced data related to the occurrence of hypophosphatemia following intravenous (IV) iron treatment at a podium presentation at the 2017 American Society of Nephrology (ASN) annual meeting in New Orleans. The impact of the use of IV iron on phosphate metabolism was assessed as a secondary exploratory endpoint of the Phase 3 randomized, double-blind, non-inferiority clinical trial of Feraheme® (ferumoxytol) and Injectafer® (ferric carboxymaltose injection). This study was comprised of approximately 2,000 adult patients with iron deficiency anemia regardless of the cause who had failed or could not tolerate oral iron... More
November 6, 2017 7:50 AM EST
Jefferies lowered its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $16.00 (from $34.00) while maintaining a Buy rating. Cheap valuation alone has not been enough to drive the stock in the absence of management execution. Instead, it's gotten cheaper.
For Makena, AMAG indicates >1 generics... More
November 2, 2017 1:23 PM EDT
Cantor Fitzgerald lowered its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $17.00 (from $21.00) while maintaining a Neutral rating following Q3 results.
Analyst William Tanner said 2018 guidance unlikely until the dust settles.
...
More
